መነሻIMGN • BMV
add
ImmunoGen Ord Shs
የቀዳሚ መዝጊያ
$268.50
የዓመት ክልል
$268.50 - $268.50
የገበያው አጠቃላይ ዋጋ
8.72 ቢ USD
የዋጋ/ገቢ ምጥጥን
-
የትርፍ ክፍያ
-
የገበያ ዜና
ፋይናንስ
የገቢ መግለጫ
ገቢ
የተጣራ ገቢ
| (USD) | ሴፕቴ 2023info | ከዓመት ዓመት ለውጥ |
|---|---|---|
ገቢ | 113.42 ሚ | 637.72% |
የሥራ ወጪ | 37.74 ሚ | 12.26% |
የተጣራ ገቢ | 30.75 ሚ | 139.54% |
የተጣራ የትርፍ ክልል | 27.11 | 105.36% |
ገቢ በሼር | 0.10 | 132.26% |
EBITDA | 26.38 ሚ | 134.26% |
ውጤታማ የግብር ተመን | -3.94% | — |
ቀሪ ሒሳብ ሉሆች
አጠቃላይ ንብረቶች
አጠቃላይ ተጠያቂነቶች
| (USD) | ሴፕቴ 2023info | ከዓመት ዓመት ለውጥ |
|---|---|---|
ጥሬ ገንዘብና የአጭር ጊዜ መዋዕለ ንዋይ | 605.54 ሚ | 95.64% |
አጠቃላይ ንብረቶች | 822.10 ሚ | 129.13% |
አጠቃላይ ተጠያቂነቶች | 260.50 ሚ | 44.09% |
አጠቃላይ እሴት | 561.60 ሚ | — |
የሼሮቹ ብዛት | 266.26 ሚ | — |
የገበያ ዋጋ እና የተገለጸ ዋጋ | 127.25 | — |
የእሴቶች ተመላሽ | 8.45% | — |
የካፒታል ተመላሽ | 10.17% | — |
የገንዘብ ፍሰት
የተጣራ ዝርዝር ገንዘብ በጥሬ ገንዘብ
| (USD) | ሴፕቴ 2023info | ከዓመት ዓመት ለውጥ |
|---|---|---|
የተጣራ ገቢ | 30.75 ሚ | 139.54% |
ከክወናዎች የተገኘ ጥሬ ገንዘብ | 2.77 ሚ | 104.31% |
ገንዘብ ከኢንቨስትመንት | -1.35 ሚ | -124.92% |
ገንዘብ ከፋይናንስ | 32.13 ሚ | 7,056.35% |
የተጣራ ዝርዝር ገንዘብ በጥሬ ገንዘብ | 33.55 ሚ | 152.12% |
ነፃ የገንዘብ ፍሰት | -2.32 ሚ | 91.72% |
ስለ
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.
An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity.
In November 2023, AbbVie, an American pharmaceutical company, announced it was buying ImmunoGen for $10.1 billion. Wikipedia
ዋና ሥራ አስፈጻሚ
የተመሰረተው
1981
ዋና መሥሪያ ቤት
ድህረገፅ
ሠራተኞች
277
